Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
about
Cerebral Cavernous Malformations: Review of the Genetic and Protein-Protein Interactions Resulting in Disease PathogenesisRHO binding to FAM65A regulates Golgi reorientation during cell migrationKLF4 is a key determinant in the development and progression of cerebral cavernous malformations.Combined HMG-COA reductase and prenylation inhibition in treatment of CCM.The pathobiology of vascular malformations: insights from human and model organism genetics.Defective autophagy is a key feature of cerebral cavernous malformations.Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.Introduction to cerebral cavernous malformation: a brief review.The third path of tubulointerstitial fibrosis: aberrant endothelial secretome.Beyond multiple mechanisms and a unique drug: Defective autophagy as pivotal player in cerebral cavernous malformation pathogenesis and implications for targeted therapies.Oxidative stress and inflammation in cerebral cavernous malformation disease pathogenesis: Two sides of the same coin.The molecular basis of endothelial cell plasticity.When endothelial cells go rogue.Elisabetta Dejana: Probing the vagaries of vessels.Endothelial-to-mesenchymal transition in cardiovascular diseases: Developmental signaling pathways gone awry.RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.In Brief: Endothelial-to-mesenchymal transition.Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformationsSystematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations
P2860
Q28072671-04912E08-31E0-4E59-B0D1-B7A10D1E6C02Q29147496-E2BB8889-0512-4814-B290-962490B9924EQ30278010-3C0D59C4-2DA8-4279-AD8A-0E08F511FFABQ33737847-44E79B75-5818-4042-AF4B-78FF0B9E3586Q34544980-91EAEF50-E839-4259-B2B7-70BE60827B03Q36278717-C8CA09C0-8A64-40DC-B4FC-A301F57825FDQ36892606-AA483542-5A46-48C0-ACB9-A1D9596FF651Q37351147-8EE1CE1F-C344-4F0F-AE75-84EE19876D36Q38687181-0DD2355F-B4D5-446B-8984-349C73F3BE8FQ38824364-FAE34F2C-48AF-46AC-93DC-624D915BBCEAQ38957623-A2B343EB-34A0-4CF7-9A9D-E20A184DCA15Q39127982-5E8CF41F-DEF7-4D25-899C-B42A0AF78D96Q41880390-BE550883-75A6-4127-96CA-06997E955E89Q42573530-6E2A108D-2A8F-4B7E-8D57-8061508AACCCQ48096975-8F04E51F-B569-4A28-921A-F2E2BAE6F317Q48419319-089BCA71-70F4-4D24-96FA-058A2AA5067DQ51693996-C8C8CF03-903E-406B-B4EF-75C225AE4EA2Q58699724-2AFE3FB8-48D4-4151-8306-F0E0D87C5263Q58764066-BA9E03A2-C1D7-4B00-A817-A851894A90A3
P2860
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
@ast
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
@en
type
label
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
@ast
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
@en
prefLabel
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
@ast
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
@en
P2093
P2860
P50
P356
P1476
Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice.
@en
P2093
Costanza Giampietro
Elizabeth Tournier-Lasserve
Luca Bravi
Luca Ferrarini
Luigi Maddaluno
Monica Corada
Noemi Rudini
P2860
P304
P356
10.1073/PNAS.1501352112
P407
P577
2015-06-24T00:00:00Z